4.8 Article

DNMT3A Loss Drives Enhancer Hypomethylation in FLT3-ITD-Associated Leukemias

期刊

CANCER CELL
卷 29, 期 6, 页码 922-934

出版社

CELL PRESS
DOI: 10.1016/j.ccell.2016.05.003

关键词

-

资金

  1. Robert and Janice McNair Foundation
  2. CPRIT [RP110028, RP110471, RP150292]
  3. NIH [DK092883, CA183252, CA193466, HG007538]
  4. Samuel Waxman Cancer Research Foundation
  5. Adrienne Helis Malvin Foundation
  6. Biotechnology and Biological Sciences Research Council [BB/I00050X/1] Funding Source: researchfish
  7. Cancer Research UK [12765] Funding Source: researchfish
  8. Medical Research Council [MC_PC_12009] Funding Source: researchfish
  9. National Institute for Health Research [NF-SI-0512-10079] Funding Source: researchfish
  10. BBSRC [BB/I00050X/1] Funding Source: UKRI

向作者/读者索取更多资源

DNMT3A, the gene encoding the de novo DNA methyltransferase 3A, is among the most frequently mutated genes in hematologic malignancies. However, the mechanisms through which DNMT3A normally suppresses malignancy development are unknown. Here, we show that DNMT3A loss synergizes with the FLT3 internal tandem duplication in a dose-influenced fashion to generate rapid lethal lymphoid or myeloid leukemias similar to their human counterparts. Loss of DNMT3A leads to reduced DNA methylation, predominantly at hematopoietic enhancer regions in both mouse and human samples. Myeloid and lymphoid diseases arise from transformed murine hematopoietic stem cells. Broadly, our findings support a role for DNMT3A as a guardian of the epigenetic state at enhancer regions, critical for inhibition of leukemic transformation.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.8
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据